SLT a consistent and effective treatment

Article

Selective laser trabeculoplasty (SLT) is an effective treatment for glaucoma and offers good long term outlooks, according to Madhu Nagar of the Clayton Eye Centre, UK.

Selective laser trabeculoplasty (SLT) is an effective treatment for glaucoma and offers good long term outlooks, according to Madhu Nagar of the Clayton Eye Centre, UK.

Nagar, speaking at the Ellex symposium, presented the results of a retrospective analysis of case notes from consecutive SLT procedures conducted between January 2000 and December 2005. A total of 546 eyes of 315 patients underwent the procedure, 80% of these had primary open-angle glaucoma, the remaining 20% had ocular hypertension. 279 eyes (51%) received SLT as a primary treatment, 267 (49%) as an adjunctive treatment and 89 eyes underwent it as a retreatment or enhancement (only 61 of these case notes were analysed).

In the primary group, a 33% mean reduction in intraocular pressure (IOP) was recorded. In the secondary group this figure was 32.6% and for those receiving SLT as a retreatment there was a 29% drop in IOP. The number of eye drops being used fell from 1.8 preoperatively, to 0.86 postoperatively.

Nagar found that the higher the preoperative IOP, the more successful the outcomes. She also found that the angle of treatment had an effect on the success of the procedure: those undergoing 90° treatment had an average IOP reduction of 26%, 180° treatment offered a 27.5% reduction and 360° provided an average reduction of 39%. She noted that 90° treatments were the most likely to fail, although this was still relatively uncommon.

Further analysis of the results found that, at week one, 5% (30/546) of the patients had not responded to the treatment and 20% were slow responders, however 60% of these became more responsive at month one.

Nagar concluded that SLT offers significant reductions in IOP and reduces the number of topical medications required by patients. She is now so confident in the procedure that she offers it as a standard treatment at her clinic.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.